GO:0001734 mRNA m(6)A methyltransferase activity: Mechanism, Genes and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0001734 describes the enzymatic activity that deposits N6-methyladenosine (m6A) on mRNA adenosines within the RRACH consensus sequence, using S-adenosyl-L-methionine (SAM) as the methyl donor.
• The core m6A writer complex is built around METTL3 as the catalytic subunit, with METTL14 as an essential RNA-binding partner, and is further modulated by WTAP and other accessory proteins.
• m6A methylation is reversible and dynamic, and it controls mRNA stability, splicing, export, and translation, thereby influencing essentially every step of the mRNA life cycle.
• METTL3-dependent m6A marks promote translation of key oncoproteins and sustain myeloid leukaemia and other cancers, making this activity a therapeutic target.
• m6A methylation is critical for immune homeostasis, including T cell maintenance through the IL-7/STAT5/SOCS pathways, and for microglial neuroinflammatory responses.
• CRISPR-based knockout, point-mutation, knock-in, and overexpression models, together with m6A mapping and Ribo-seq, are the standard toolkit for dissecting GO:0001734 function.
Description
GO:0001734, mRNA m(6)A methyltransferase activity, is the molecular function that catalyzes the transfer of a methyl group from S-adenosyl-L-methionine (SAM) to an adenosine within mRNA, producing N6-methyladenosine (m6A) and S-adenosyl-L-homocysteine. This activity is the central writer step of the epitranscriptome and is directed to adenosines embedded in the RRACH consensus sequence, where R is a purine and H is C, A, or U. Because m6A is the most abundant internal modification in eukaryotic mRNA, the enzyme activity defined by GO:0001734 sits at the interface of transcription, RNA processing, and translation. Researchers care about GO:0001734 because it is a reversible and highly regulated activity that shapes transcript fate. The m6A mark installed by this activity is read by dedicated reader proteins that influence mRNA stability, splicing, nuclear export, and translation efficiency. Consequently, perturbations of this activity produce broad transcriptomic and proteomic consequences, from altered stem cell differentiation to immune dysregulation and oncogenic transformation. From a methodological standpoint, GO:0001734 is studied with a combination of genetic perturbation, m6A mapping, and translation profiling. CRISPR knockout of the catalytic subunit, point mutations that disable SAM binding, and targeted m6A editing with Cas13-directed methyltransferases are all used to establish causality between this activity and downstream phenotypes. This article summarizes the mechanism, key genes, disease links, and research models for GO:0001734.
mRNA m(6)A methyltransferase activity At A Glance
| GO ID | GO:0001734 |
|---|---|
| GO term | mRNA m(6)A methyltransferase activity |
| Ontology | molecular_function |
| Synonym | mRNA (N6-adenosine)-methyltransferase activity |
| Major function | Catalyzes methylation of adenosine in mRNA to N6-methyladenosine using SAM as methyl donor |
| Reaction | an adenosine in mRNA + S-adenosyl-L-methionine = an N(6)-methyladenosine in mRNA + H+ + S-adenosyl-L-homocysteine |
| Consensus sequence | RRACH (R = purine; H = C, A, or U) |
| Cofactor | S-adenosyl-L-methionine (SAM) |
| Representative enzymes | METTL3, METTL14, WTAP-associated writer complex |
What Is GO:0001734?
GO:0001734 is defined as the catalysis of the reaction in which an adenosine in mRNA plus S-adenosyl-L-methionine yields an N6-methyladenosine in mRNA plus H+ plus S-adenosyl-L-homocysteine. In simpler terms, it is the activity that writes the m6A mark onto mRNA. The activity is sequence-context dependent and preferentially methylates adenosines within the RRACH consensus motif, where R is a purine and H is C, A, or U. It is a molecular_function term in the Gene Ontology and is synonymous with mRNA (N6-adenosine)-methyltransferase activity.
Why Is mRNA m(6)A methyltransferase activity Important in Cell Biology?
GO:0001734 is important because the m6A mark it installs is a dynamic and reversible epitranscriptomic signal that controls the fate of thousands of mRNAs. By regulating mRNA stability, splicing, export, and translation, this activity influences cell differentiation, immune homeostasis, and oncogenesis. Its centrality to gene expression makes it both a fundamental research topic and a candidate therapeutic target in cancer, neuroinflammation, and immune disorders.
• Controls mRNA stability, splicing, nuclear export, and translation efficiency through the m6A mark.
• Promotes translation of oncoproteins and sustains myeloid leukaemia, making it a cancer dependency.
• Regulates hematopoietic stem and progenitor cell differentiation and leukemogenesis.
• Maintains T cell homeostasis via the IL-7/STAT5/SOCS pathways.
• Drives neuroinflammation and neurotoxicity in microglia by stabilizing BATF mRNA.
• Is essential for normal development and stem cell self-renewal.
• Provides a programmable target for Cas13-directed m6A editing.
• Can exert m6A-independent functions through related enzymes such as METTL16, highlighting context dependence.
• Serves as a biomarker and therapeutic target in multiple malignancies.
• Is a core component of the epitranscriptome and a model system for studying reversible RNA modifications.
Molecular Mechanism of mRNA m(6)A methyltransferase activity
Substrate recognition and RRACH consensus
In simple terms: The enzyme only methylates adenosines that sit in a specific short sequence pattern in mRNA.
The activity defined by GO:0001734 preferentially targets adenosines within the RRACH consensus motif, where R is a purine and H is C, A, or U. This sequence preference ensures that only a subset of adenosines in the transcriptome become m6A sites, and it underlies the reproducible m6A maps observed across cell types. The catalytic subunit METTL3 and its partner METTL14 together form the RNA-binding interface that positions the target adenosine for methylation.
Catalytic transfer of the methyl group from SAM
In simple terms: The enzyme takes a methyl group from SAM and attaches it to the adenosine.
The reaction catalyzed by GO:0001734 uses S-adenosyl-L-methionine (SAM) as the methyl donor and produces N6-methyladenosine plus S-adenosyl-L-homocysteine. METTL3 is the catalytic subunit that carries out this methyl transfer, while METTL14 contributes to RNA binding and substrate positioning. Disruption of the catalytic site abolishes m6A deposition and alters translation of target transcripts.
Writer complex assembly and accessory proteins
In simple terms: Several proteins come together to form the m6A writer machine.
The core m6A writer is a heterodimer of METTL3 and METTL14, which associates with accessory proteins such as WTAP to form a functional methyltransferase complex. This assembly is required for efficient m6A deposition on mRNA and for the downstream effects on transcript fate. Perturbation of complex components alters global m6A levels and affects processes such as hematopoietic differentiation and leukaemogenesis.
Coupling to transcription and promoter-bound methylation
In simple terms: The writer can act while the mRNA is still being made, linking methylation to transcription.
Promoter-bound METTL3 maintains myeloid leukaemia by m6A-dependent translation control, indicating that the activity can be coupled to active transcription. This coupling allows m6A to be deposited co-transcriptionally and to influence the fate of newly synthesized transcripts. Such promoter-associated methylation expands the regulatory reach of GO:0001734 beyond post-transcriptional events.
Reversibility and dynamic regulation
In simple terms: The m6A mark can be removed, so the activity is balanced by erasers.
m6A is a reversible modification, and the activity defined by GO:0001734 is counterbalanced by demethylases that remove the mark. This dynamic balance allows cells to rapidly remodel the epitranscriptome in response to developmental and environmental cues. The reversibility also makes the activity amenable to therapeutic modulation and to programmable editing approaches.
Programmable m6A editing
In simple terms: Scientists can now direct the methyltransferase to chosen RNAs using Cas13.
Cas13-directed methyltransferase systems enable programmable m6A modification of cellular RNAs, allowing site-specific installation of the mark. These tools use catalytically inactive Cas13 fused to a methyltransferase domain to target specific transcripts. Such programmable editing provides a powerful way to test the causal role of individual m6A sites in mRNA fate and phenotype.
Key Genes Involved in GO:0001734 mRNA m(6)A methyltransferase activity
The following genes and proteins are central to the activity defined by GO:0001734, either as catalytic subunits, complex components, or context-dependent regulators.
| Gene | Major Role | Research Relevance |
|---|---|---|
| METTL3 | Catalytic subunit that transfers methyl from SAM to mRNA adenosine | Core writer; knockout abolishes m6A and alters translation |
| METTL14 | RNA-binding partner that stabilizes the complex and positions substrate | Essential for m6A deposition; regulates stem cell differentiation |
| WTAP | Accessory protein that supports writer complex assembly and localization | Modulates m6A levels and complex function |
| METTL16 | Related methyltransferase with m6A-independent functions | Context-dependent regulator of translation and tumorigenesis |
| FTO | Demethylase that removes m6A | Balances the activity and affects mRNA fate |
| ALKBH5 | Demethylase that removes m6A | Counteracts writer activity and influences development |
| YTHDF1 | Reader that recognizes m6A and promotes translation | Links m6A to translation efficiency |
| YTHDF2 | Reader that promotes mRNA degradation | Links m6A to transcript stability |
| YTHDC1 | Nuclear reader involved in splicing and export | Connects m6A to RNA processing |
| IGF2BP1 | Reader that stabilizes m6A-marked transcripts | Modulates oncogenic mRNA stability |
| HNRNPA2B1 | Reader involved in splicing and processing | Links m6A to RNA maturation |
| BATF | Transcription factor whose mRNA is stabilized by m6A in microglia | Mediates neuroinflammation downstream of METTL3 |
| SOCS1 | Negative regulator of cytokine signaling affected by m6A | Part of IL-7/STAT5/SOCS axis in T cells |
| SOCS3 | Negative regulator of cytokine signaling affected by m6A | Part of IL-7/STAT5/SOCS axis in T cells |
| IL7R | Receptor whose expression is influenced by m6A | Controls T cell homeostasis |
| STAT5 | Transcription factor in the IL-7 signaling pathway | Effector of m6A-dependent T cell maintenance |
| SP1 | Transcription factor implicated in promoter-bound METTL3 function | Contributes to leukaemia maintenance |
| MYC | Oncogene whose translation can be influenced by m6A | Downstream target of METTL3 in cancer |
How Is mRNA m(6)A methyltransferase activity Regulated?
The activity defined by GO:0001734 is regulated at multiple levels, including complex assembly, substrate availability, and the balance between writers and erasers. Promoter-bound METTL3 can couple methylation to active transcription, providing a mechanism for locus-specific regulation. In immune cells, m6A methylation is integrated with cytokine signaling pathways such as IL-7/STAT5/SOCS, which shape T cell homeostasis. In microglia, METTL3-dependent m6A stabilization of BATF mRNA links the activity to neuroinflammatory gene programs. Reversibility through demethylases further allows dynamic tuning of m6A levels in response to cellular state.
mRNA m(6)A methyltransferase activity and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| METTL3 | Myeloid leukaemia; neuroinflammation | Knockout and point-mutation cell models; microglial models |
| METTL14 | Leukemogenesis; hematopoietic differentiation | Knockout and overexpression models in hematopoietic cells |
| METTL16 | Tumorigenesis; translation control | Knockout and rescue models |
| BATF | Neuroinflammatory gene program | Knock-in and reporter models in microglia |
| SOCS1/SOCS3 | T cell homeostasis and cytokine signaling | Knockout and overexpression models in T cells |
Cancer and leukaemia
METTL3-dependent m6A methylation promotes translation of oncoproteins and sustains myeloid leukaemia, and promoter-bound METTL3 maintains leukaemic gene expression programs. METTL14 inhibits hematopoietic stem and progenitor differentiation while promoting leukemogenesis through mRNA m6A modification, highlighting the importance of writer complex components in blood cancers. These findings establish GO:0001734 as a cancer dependency and a candidate therapeutic target.
Neuroinflammation and neurotoxicity
The m6A methyltransferase METTL3 drives neuroinflammation and neurotoxicity by stabilizing BATF mRNA in microglia, directly linking the activity to inflammatory gene programs in the brain. This places GO:0001734 in the mechanistic landscape of neuroinflammatory disease and suggests that modulating the activity could influence microglial responses.
Immune homeostasis and T cell biology
m6A mRNA methylation controls T cell homeostasis by targeting the IL-7/STAT5/SOCS pathways, demonstrating that the activity is required for normal immune cell maintenance. Dysregulation of this axis can alter cytokine signaling and immune balance, connecting GO:0001734 to immune disorders.
Therapeutic potential and programmable editing
m6A RNA methylation is considered a therapeutic opportunity because the mark is reversible and central to gene expression control. Programmable m6A modification with Cas13-directed methyltransferases offers a route to site-specific manipulation of the activity for research and potential therapy. METTL16 exerts m6A-independent functions in translation and tumorigenesis, underscoring the need for precise targeting strategies.
From mRNA m(6)A methyltransferase activity-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does loss of catalytic activity abolish m6A deposition? | METTL3 catalytic-dead point-mutation knock-in |
| Which transcripts depend on m6A for translation? | METTL3 knockout with Ribo-seq and RNA-seq |
| How does m6A affect T cell homeostasis? | Knockout models in T cells with IL-7/STAT5/SOCS readouts |
| Can m6A be installed at a specific transcript? | Cas13-directed methyltransferase targeting |
| What is the role of METTL14 in differentiation? | Knockout and overexpression in hematopoietic progenitors |
| How does promoter-bound METTL3 sustain leukaemia? | Tagged knock-in and chromatin-associated models |
How to Study the mRNA m(6)A methyltransferase activity Process
| Method | What It Measures | Typical Application |
|---|---|---|
| m6A-seq / MeRIP-seq | Transcriptome-wide m6A sites | Mapping writer targets and validating perturbations |
| Ribo-seq | Ribosome occupancy and translation efficiency | Linking m6A to protein output |
| RNA-seq | Steady-state transcript levels | Identifying m6A-dependent expression changes |
| RNA stability assay | Decay rates of marked transcripts | Distinguishing stabilization from degradation |
| Cas13-directed m6A editing | Site-specific methylation | Testing causality of individual m6A sites |
| Western blot / proteomics | Protein abundance and modifications | Confirming downstream effects |
| Reporter assays | Methylation-dependent translation or stability | Mechanistic dissection of m6A function |
| CRISPR knockout screening | Gene dependencies linked to the activity | Identifying modifiers of m6A biology |
m6A mapping and quantification
Mapping m6A sites transcriptome-wide is the primary way to measure the output of GO:0001734. Antibody-based enrichment and sequencing approaches reveal consensus RRACH sites and allow comparison between wild-type and perturbed cells. These maps are essential for linking the activity to specific transcripts and for validating CRISPR models.
Translation profiling with Ribo-seq
Ribo-seq measures ribosome occupancy and translation efficiency, which is a key downstream readout of m6A methylation. METTL3-dependent m6A marks promote translation of target mRNAs, and Ribo-seq can quantify these effects. Combining Ribo-seq with m6A mapping provides a direct link between the activity and protein output.
RNA-seq and transcript stability assays
RNA-seq measures steady-state transcript levels, while stability assays measure decay rates of m6A-marked mRNAs. Because m6A can promote either stability or degradation depending on the reader, these assays are needed to interpret the functional consequence of the activity. They are commonly paired with knockout or point-mutation models.
Programmable editing and reporter systems
Cas13-directed methyltransferase systems allow site-specific installation of m6A on chosen transcripts, enabling causal tests of individual sites. Reporter systems can be used to monitor methylation-dependent translation or stability in real time. These approaches complement global perturbation studies and increase mechanistic resolution.
How CRISPR Can Be Used to Study GO:0001734 mRNA m(6)A methyltransferase activity
Knockout
CRISPR knockout of METTL3 or METTL14 abolishes the activity defined by GO:0001734 and reduces global m6A levels, providing a clean loss-of-function background for mechanistic studies. Knockout models have been used to show that m6A promotes translation of oncoproteins and sustains leukaemia. They are also used to study immune and neuroinflammatory phenotypes.
Point Mutation
Catalytic-dead point mutations in METTL3 allow separation of methyltransferase activity from scaffolding functions, which is critical for assigning phenotypes specifically to GO:0001734. Point-mutation knock-in models can reveal whether m6A catalysis, rather than protein presence, drives a given phenotype. Such models are especially valuable when interpreting complex cancer dependencies.
Knock-in
Tagged knock-in of METTL3 or complex components enables localization and interaction studies without overexpression artifacts. Knock-in of reader or substrate mutations can be used to test the importance of specific m6A sites or reader domains. These models complement global knockouts by preserving endogenous regulation.
Overexpression
Overexpression of METTL3 or METTL14 can increase m6A levels and is used to test sufficiency of the activity for downstream phenotypes. Overexpression models are useful for identifying transcripts that are sensitized to increased methylation. They are often paired with m6A mapping and translation profiling to define the affected network.
How EDITGENE Supports mRNA m(6)A methyltransferase activity Research
Researchers studying mRNA m(6)A methyltransferase activity-related genes often need to determine whether a candidate gene is causally involved in m6A deposition, transcript fate, or disease phenotypes. Rigorous causal inference requires well-controlled genetic models that isolate catalytic activity from scaffolding functions and that preserve endogenous regulation. EDITGENE provides a full suite of CRISPR-based cell models and screening services tailored to GO:0001734 research.
Contact EDITGENE today to design your custom CRISPR model for mRNA m(6)A methyltransferase activity research.
Frequently Asked Questions About mRNA m(6)A methyltransferase activity
What is GO:0001734?
GO:0001734 is the Gene Ontology molecular_function term for mRNA m(6)A methyltransferase activity, which catalyzes methylation of adenosine in mRNA to N6-methyladenosine using SAM as the methyl donor.
What does mRNA m(6)A methyltransferase activity do?
It installs the m6A mark on adenosines within the RRACH consensus sequence, thereby influencing mRNA stability, splicing, export, and translation.
What genes are involved in mRNA m(6)A methyltransferase activity?
The core genes include METTL3 as the catalytic subunit, METTL14 as an essential partner, and accessory factors such as WTAP, with readers and erasers shaping the downstream effects.
Which enzyme catalyzes m6A methylation of mRNA?
METTL3 is the catalytic subunit that transfers the methyl group from SAM to mRNA adenosine, working together with METTL14 and other complex components.
What is the consensus sequence for m6A methylation?
The preferred consensus is RRACH, where R is a purine and H is C, A, or U.
How is m6A methylation linked to cancer?
METTL3-dependent m6A promotes translation of oncoproteins and sustains myeloid leukaemia, while METTL14 promotes leukemogenesis, making the activity a cancer dependency.
Can m6A methylation be targeted with CRISPR?
Yes, CRISPR knockout, point-mutation knock-in, and Cas13-directed programmable editing are all used to perturb or redirect the activity.
What methods measure mRNA m6A methyltransferase activity?
m6A-seq, Ribo-seq, RNA-seq, stability assays, and reporter systems are commonly used to measure the activity and its consequences.
Is m6A methylation reversible?
Yes, m6A is reversible and is counterbalanced by demethylases such as FTO and ALKBH5.
Why is GO:0001734 important for immunology?
m6A methylation controls T cell homeostasis through the IL-7/STAT5/SOCS pathways and drives microglial neuroinflammatory programs, linking the activity to immune regulation.
Conclusion
GO:0001734, mRNA m(6)A methyltransferase activity, is a central molecular function that writes the most abundant internal mRNA modification and thereby shapes transcript fate, translation, and cell state. Its core machinery, built around METTL3 and METTL14, is implicated in cancer, immune homeostasis, and neuroinflammation, making it a high-value target for mechanistic and translational research. CRISPR-based knockout, point-mutation, knock-in, and overexpression models, combined with m6A mapping and translation profiling, provide the experimental framework needed to dissect this activity with causal rigor.
References
- 1. Wu X et al.. 2025. The m(6)A methyltransferase METTL3 drives neuroinflammation and neurotoxicity through stabilizing BATF mRNA in microglia.. Cell Death Differ 32(1):100-117 PMID: 38902548
- 2. He PC et al.. 2021. m(6) A RNA methylation: from mechanisms to therapeutic potential.. EMBO J 40(3):e105977 PMID: 33470439
- 3. Wilson C et al.. 2020. Programmable m(6)A modification of cellular RNAs with a Cas13-directed methyltransferase.. Nat Biotechnol 38(12):1431-1440 PMID: 32601430
- 4. Lin S et al.. 2016. The m(6)A Methyltransferase METTL3 Promotes Translation in Human Cancer Cells.. Mol Cell 62(3):335-345 PMID: 27117702
- 5. Li HB et al.. 2017. m(6)A mRNA methylation controls T cell homeostasis by targeting the IL-7/STAT5/SOCS pathways.. Nature 548(7667):338-342 PMID: 28792938
- 6. Su R et al.. 2022. METTL16 exerts an m(6)A-independent function to facilitate translation and tumorigenesis.. Nat Cell Biol 24(2):205-216 PMID: 35145225
- 7. Weng H et al.. 2018. METTL14 Inhibits Hematopoietic Stem/Progenitor Differentiation and Promotes Leukemogenesis via mRNA m(6)A Modification.. Cell Stem Cell 22(2):191-205.e9 PMID: 29290617
- 8. Barbieri I et al.. 2017. Promoter-bound METTL3 maintains myeloid leukaemia by m(6)A-dependent translation control.. Nature 552(7683):126-131 PMID: 29186125
